Tech Company Financing Transactions

OriCell Therapeutics Funding Round

On 4/10/2026, OriCell Therapeutics raised $110 million in funding from Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners USA and Vivo Capital.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

3F Bldg 1, No. 1227 Zhangheng Rd, Pudong,
Shanghai, 200120
CN

Phone

+8621-68868119

Website

www.oricell.com

Email Address

[email protected]

Overview

Founded in 2015, OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy. We have received a pre-A round exclusive investment of nearly 100 million yuan from Qiming Venture Partners at the end of 2019 and completed the A round of financing worth over 200 million Yuan at the end of 2020.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Yang Huanfeng

        

Chief Scientific Officer

He Xiaowen

        

Chief Technical Officer

Weidong Cui

        

Browse more venture capital transactions:

Prev: 4/10/2026: Provally venture capital transaction
Next: 4/10/2026: Hybron Technologies venture capital transaction

Share this article

About Database of VC Transactions

We do our best to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary